Compass Therapeutics, Inc. CMPX

Rank #2075 · Nasdaq · $0.1B market cap

⚠ Going-concern flag — the auditor (CohnReznick LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

34.7

P/E

-2.9

P/B

0.95

ROE

-33.2%

Op. Margin

-6661.8%

Debt Ratio

10%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -2.9x, P/B 0.95x. Ranks in the top 53% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -33.2%. Ranks in the top 92% of the universe.

Safety ★★★★★

Excellent

Debt ratio 10%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2019	–	$-0.0B	$-0.0B	$-0.0B	–	-100
2020	–	$-0.0B	$-0.0B	$-0.1B	–	-23
2021	–	$-0.0B	$-0.0B	$0.0B	–	106
2022	–	$-0.1B	$-0.1B	$0.0B	–	34
2023	–	$-0.0B	$-0.0B	$0.1B	–	13
2024	$0.0B	$-0.1B	$-0.0B	$0.2B	–	5
2025	$0.0B	$-0.1B	$-0.0B	$0.1B	-6661.8	10

← See the full screener